CORDIS Project
Funding breakdown and partner intelligence are Premium
Sign in and upgrade to Premium for EU contribution totals, consortium analytics, OpenAlex research context, and AI summaries. · 0 consortium intelligence fields visible of 1
Start free • Cancel anytime • 14-day refund guarantee
This project focuses on developing a novel therapeutic approach for lung adenocarcinoma by using Antisense Oligonucleotides to regulate pre-mRNA splicing of the NUMB gene. This innovative method aims to inhibit cancer cell proliferation and reduce tumor growth, with plans to advance towards clinical trials.
Lung cancer is the leading cause of cancer-related deaths, with 1.8 million deaths expected globally in 2021.
Lung adenocarcinomas (LUAD) represent 1/3 of all lung cancer cases.
Despite notable advances, current treatments remain ineffective, resulting in <25% survival beyond 5 years.
Due to the high heterogeneity of molecular abnormalities driving lung cancers, targeted therapies are applicable to only a small subset of patients.
There is therefore an urgent unmet need for developing novel ther…
FUNDACIO CENTRE DE REGULACIO GENOMICA
Partner organizations (coordinator is shown above), with normalized type and CORDIS activity type. Guests see up to 4 partners.
Spain, BARCELONA
Type: SME
Activity type: Private for-profit entities (excluding Higher or Secondary Education Establishments)
SME: Yes
Similar projects, consortium collaboration history, frequent partners, and OpenAlex research context.
Guests see up to 5 EuroSciVoc fields.
Guests see up to 5 topics.
Guests see up to 5 keywords.
